Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
Exclusion criteria
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Primary purpose
Allocation
Interventional model
Masking
51 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal